10-Q: Utah Medical Products Q3 2026: Revenue Dip, Acquisition Boosts Outlook

Utah Medical Products Inc. reported a 12.1% decrease in Q3 2026 revenue compared to the prior year, primarily due to the loss of two major customers, though a recent acquisition and improved operating margins offer some offset.

Summary

• Consolidated net sales for Q3 2026 were $8.621 million, a 12.1% decrease from $9.812 million in Q3 2025.
• For the nine months ended September 30, 2026, net sales were $25.873 million, down 12.2% from $29.475 million in the same period of 2025.
• Net income for Q3 2026 was $2.787 million, an increase of 5.9% from $2.631 million in Q3 2025, while nine-month net income decreased by 7.4% to $8.077 million from $8.720 million.
• The company acquired Orion Medical Supplies Ltd. in the UK on August 28, 2026, for $4.895 million, which is expected to add approximately $6 million to annual sales.
• Operating income margins improved in Q3 2026 to 32.4% from 26.6% in Q3 2025, despite lower sales, due to reduced operating expenses.
• Cash and investments stood at $85.2 million as of September 30, 2026, with no debt.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously negative due to declining revenues and the impact of lost customers, despite strategic acquisitions and improved margins on lower sales.

Positives

• Operating income margins improved to 32.4% in Q3 2026 from 26.6% in Q3 2025, driven by lower operating expenses.
• Net income for Q3 2026 increased by 5.9% to $2.787 million compared to Q3 2025.
• The acquisition of Orion Medical Supplies Ltd. is expected to add approximately $6 million in annual sales and dilute overhead expenses.
• The company maintained a strong balance sheet with $85.2 million in cash and investments and no debt.
• Diluted EPS for Q3 2026 increased by 6.8% to $0.876 from $0.820 in Q3 2025.
• The company has a stated intention to continue returning cash to stockholders through dividends and share repurchases when the stock appears undervalued.

Negatives

• Consolidated net sales decreased by 12.1% in Q3 2026 and 12.2% for the nine-month period compared to the prior year.
• Sales declined significantly due to the loss of two major customers: PendoTECH and a China-based distributor of BPM kits.
• Sales of the Filshie Clip System saw an accelerated decline of 32.7% in Q3 2026 compared to the prior year.
• New biopharm customer sales growth has been slower than anticipated.
• Nine-month net income decreased by 7.4% to $8.077 million from $8.720 million in the prior year.
• The company's full-year 2026 revenue is now projected to be 7%-8% lower than in 2025, a revision from earlier expectations.

Risks

• The company faces risks related to foreign currency exchange rate fluctuations impacting its international operations.
• The loss of key customers and the slow development of new sales channels pose a significant risk to revenue growth.
• The company is involved in ongoing litigation, specifically Filshie clip U.S. product liability lawsuits, although the outcome is not expected to be material.
• Future results could be materially affected by risks and uncertainties detailed in the company's Form 10-K, including those not currently known or deemed immaterial.
• The integration of Orion Medical Supplies Ltd. and the realization of its expected benefits carry inherent risks.

Future Outlook

The company projects a 7%-8% decrease in total USD revenues for the full year 2026 compared to 2025, with EPS estimated to be around $3.60 per share, up from $3.48 in 2025. Management plans to invest in new technology, pursue accretive acquisitions, and return cash to stockholders via dividends and share repurchases if the stock is undervalued.

Management Comments

• Management believes that current cash balances, income from operations and effective management of working capital will provide the liquidity needed to finance internal growth plans.
• The company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders.
• Management believes that UTMDs working capital rationalization after the Orion acquisition will remain sufficient to meet normal operating needs, as well as providing a cushion for unpredictable short-term negative events, new capital expenditures and continued cash dividend payments to stockholders.

Industry Context

StockSavvy.ai notes that the medical device industry is experiencing shifts due to customer concentration and evolving market demands. Utah Medical Products' challenges with lost customers highlight the risks of over-reliance on a few large accounts, while their acquisition strategy aims to diversify revenue streams and leverage existing infrastructure, a common tactic in the sector to drive growth and efficiency.

Comparison to Industry Standards

• The company's operating income margin of 32.4% in Q3 2026 is strong, especially considering the revenue decline, suggesting efficient cost management relative to sales.
• The gross profit margin of 56.1% in Q3 2026, while slightly down from 57.1% in Q3 2025, remains robust for a medical device manufacturer.
• The company's debt-to-asset ratio of 4% is exceptionally low, indicating a very conservative financial structure compared to many industry peers who may utilize more leverage.
• The reported Return on Equity (ROE) of 9% for 9M 2026 (annualized, before dividends) is below the target of 20%, suggesting room for improvement in profitability relative to shareholder equity.

Legal Proceedings

• The company is involved in Filshie clip U.S. product liability lawsuits, with most having received dismissals. The outcome of remaining litigation is not expected to be material to consolidated financial results.

Stakeholder Impact

• Shareholders may see continued returns through dividends and share repurchases, but the recent revenue decline and slower-than-expected new sales growth could temper short-term stock performance.
• Employees may be impacted by the integration of Orion Medical Supplies and the company's focus on operational efficiency.
• Customers may benefit from the acquisition of Orion Medical, potentially expanding product offerings and geographic reach, though the loss of key suppliers like PendoTECH could affect some biopharma clients.
• Creditors are not significantly impacted as the company has no long-term debt and maintains a strong cash position.

Next Steps

• Finalize valuation and purchase price allocation for the Orion Medical Supplies Ltd. acquisition.
• Integrate Orion Medical Supplies operations into Femcare's existing facilities.
• Continue to monitor and manage working capital following the Orion acquisition.
• Pursue new sales from high-pressure process control transducer configurations to biopharmaceutical manufacturers.
• Seek to regain OUS business impacted by trade policies.
• Work towards a favorable conclusion of Filshie Clip System product liability lawsuits in the U.S.
• Introduce additional clinician-helpful products through product development.
• Continue opportunistic open market share repurchases if the stock price is deemed undervalued.

Key Dates

Recommendation

The company's revenue decline and customer loss are significant concerns, warranting a cautious approach. However, the improved operating margins, successful acquisition of Orion Medical, strong balance sheet, and commitment to shareholder returns provide a basis for holding the stock. Further clarity on the integration of Orion and the success of new sales initiatives will be crucial for a more positive outlook.

Keywords

medical devices, revenue decline, acquisition, Orion Medical Supplies, Filshie Clip System, operating income, gross profit margin, cash flow